# MOLECULAR MECHANISMS OF CELLULAR AGING AND REJUVENATION STRATEGIES
## PART 2 OF 3: HALLMARKS 5-9 & REJUVENATION STRATEGIES

**A Comprehensive Research Review**

Author: Alice Frolov  
Field: Aging Biology, Molecular Biology, Biotechnology  
Date: February 2026  
Document Type: Comprehensive Scientific Review  

---

## TABLE OF CONTENTS - PART 2

### II. MOLECULAR PATHWAYS OF AGING (CONTINUED)

**II.E CELLULAR SENESCENCE**  
2.17 Discovery and Definition of Senescence  
2.18 The Senescence-Associated Secretory Phenotype (SASP)  
2.19 Accumulation of Senescent Cells with Aging  

**II.F STEM CELL EXHAUSTION**  
2.20 Stem Cells: Guardians of Tissue Renewal  
2.21 Age-Related Changes in Stem Cells  
2.22 Intrinsic vs. Extrinsic Contributions  
2.23 Reversibility: Can Stem Cell Function Be Restored?  

**II.G LOSS OF PROTEOSTASIS**  
2.24 Proteostasis Networks: Maintaining Protein Quality  
2.25 Proteostasis Decline with Aging  
2.26 Protein Aggregation Diseases and Aging  

**II.H ALTERED INTERCELLULAR COMMUNICATION**  
2.27 Inflammation and Inflammaging  
2.28 Extracellular Matrix Remodeling  
2.29 Endocrine Changes  

### III. REJUVENATION STRATEGIES

**III.A PHARMACOLOGICAL INTERVENTIONS**  
3.1-3.6 Senolytics: Selective Elimination of Senescent Cells  
3.7-3.14 NAD⁺ Precursors: Restoring Cellular Energy  
3.15-3.20 mTOR Inhibitors: Rapamycin and Rapalogs  

**III.B EPIGENETIC REPROGRAMMING**  
3.21-3.27 Yamanaka Factors and Partial Reprogramming  

**III.C CRISPR APPLICATIONS**  
3.28-3.29 Gene Editing and Epigenome Editing  

**III.D STEM CELL THERAPIES**  
3.30-3.34 HSC, MSC, and iPSC-Derived Therapies  

---

# II.E CELLULAR SENESCENCE

## 2.17 Discovery and Definition of Senescence

**Leonard Hayflick's 1961 discovery:** Human fibroblasts in culture divide ~50 times then enter irreversible growth arrest—"replicative senescence" or "Hayflick limit." This overturned Alexis Carrel's claim (1912) that cells are immortal in culture (Carrel's cultures were contaminated with fresh cells).

**Definition:** Cellular senescence is a state of stable cell cycle arrest accompanied by:

1. **Proliferative arrest:** Cannot divide despite mitogenic stimuli. Not quiescence (which is reversible).

2. **Apoptosis resistance:** Upregulation of anti-apoptotic proteins (BCL-2, BCL-xL). Senescent cells resist death signals.

3. **Metabolic alterations:** Increased protein synthesis, autophagy dysregulation, mitochondrial dysfunction, increased ROS.

4. **Senescence-associated secretory phenotype (SASP):** Secretion of pro-inflammatory cytokines, chemokines, proteases, growth factors.

5. **Chromatin alterations:** Senescence-associated heterochromatic foci (SAHF), DNA damage foci (γ-H2AX), p16 expression.

**Types of senescence:**

**Replicative senescence:** Triggered by telomere shortening. After ~50 divisions, telomeres critically short → DNA damage response → p53/p21 and p16/Rb activation → arrest.

**Stress-induced premature senescence (SIPS):** Triggered by:
- Oxidative stress (excessive ROS)
- DNA damage (radiation, chemotherapy)
- Oncogene activation (hyperactive RAS, BRAF → oncogene-induced senescence/OIS)
- Mitochondrial dysfunction
- Chromatin disruption

**Pathways:**

**p53/p21:** DNA damage → ATM/ATR → p53 → p21 (CDKN1A) → CDK2 inhibition → Rb hypophosphorylated → E2F sequestered → G1 arrest.

**p16/Rb:** Stress → p16 (CDKN2A) expression → CDK4/6 inhibition → Rb hypophosphorylated → arrest.

These pathways converge on Rb hypophosphorylation.

## 2.18 The Senescence-Associated Secretory Phenotype (SASP)

The SASP comprises >80 secreted factors:

**Cytokines:**
- Pro-inflammatory: IL-1α, IL-1β, IL-6, IL-8, TNF-α
- Chemokines: MCP-1 (CCL2), MIP-1α (CCL3), GRO-α (CXCL1)

**Growth factors:** VEGF, HGF, FGF, amphiregulin

**Proteases:** MMP-1, MMP-3, MMP-9, MMP-12 (degrade ECM), uPA

**Functions (beneficial in acute settings):**

**Wound healing:** SASP attracts immune cells, promotes angiogenesis (VEGF), remodels ECM. Senescent cells appear transiently in wounds, then cleared.

**Tumor suppression:** OIS prevents proliferation of oncogenic cells. SASP recruits NK cells and macrophages to eliminate pre-cancerous cells.

**Embryonic development:** Senescent cells guide morphogenesis during development, then cleared.

**Dysfunction (chronic in aging):**

With aging, senescent cells accumulate and SASP becomes chronic:

**1. Chronic inflammation ("inflammaging"):**
- IL-6, IL-1, TNF-α create pro-inflammatory environment
- Drives cardiovascular disease, diabetes, neurodegeneration, cancer, frailty

**2. Paracrine senescence:**
- SASP induces senescence in neighboring cells (bystander effect)
- IL-1α, IL-6 activate NF-κB → p16 induction → senescence
- Creates spreading senescence, amplifying burden

**3. Stem cell dysfunction:**
- SASP impairs satellite cells, HSCs, neural stem cells
- Promotes differentiation over self-renewal

**4. Tissue remodeling:**
- MMPs degrade ECM → lung emphysema, skin wrinkles, vascular aneurysm

**5. Cancer promotion:**
- While OIS suppresses early tumorigenesis, SASP promotes established tumors
- IL-6, IL-8 → EMT; VEGF → angiogenesis; MMPs → invasion/metastasis
- Paradox: senescence both suppresses and promotes cancer

**SASP regulation:**

**NF-κB:** Central regulator. Inhibiting NF-κB reduces SASP without eliminating arrest.

**mTOR:** SASP requires protein synthesis. Rapamycin reduces SASP ("senomorphic" effect).

**cGAS-STING:** Cytosolic DNA activates → type I interferons

## 2.19 Accumulation of Senescent Cells with Aging

**Quantification:**
- Young tissues: <1-5% senescent cells
- Aged tissues (80 years):
  - Skin: ~10-15%
  - Adipose: ~15-20%
  - Liver: ~5-10%
  - Kidney: ~10-15%

**Markers:**
- **p16 (CDKN2A):** Increased expression (not perfectly specific)
- **SA-β-gal:** Lysosomal β-gal at pH 6.0 (widely used, not perfectly specific)
- **γ-H2AX foci:** Persistent DNA damage
- **SASP factors:** IL-6, IL-8 secretion

**Why accumulation?**

**Increased generation:** More stress with age (oxidative damage, DNA damage, mitochondrial dysfunction)

**Decreased clearance:**
- Immune surveillance decline (NK cells, macrophages)
- Apoptosis resistance (BCL-2, BCL-xL)
- SASP self-protection (autocrine IL-6)

**Evidence for causality:**

**Transplantation:** Injecting senescent cells into young mice → physical dysfunction, reduced lifespan (Baker et al., 2016)

**Genetic clearance (INK-ATTAC mice):**
- Baker et al. (2011): p16+ cell elimination via drug-inducible caspase-8
- Lifelong clearance: Delays pathology, extends median lifespan ~20-30%
- Late-life clearance: Improves healthspan, attenuates diseases

**Conclusion:** Senescent cells causally contribute to aging.

---

# II.F STEM CELL EXHAUSTION

## 2.20 Stem Cells: Guardians of Tissue Renewal

Adult stem cells maintain tissue homeostasis through self-renewal and differentiation.

**Key populations:**

**Hematopoietic stem cells (HSCs):** Bone marrow, generate all blood cells. Mostly quiescent (~95% in G0).

**Muscle satellite cells:** Beneath basal lamina of muscle fibers. Activated by injury. Pax7+.

**Neural stem cells (NSCs):** SVZ and hippocampal SGZ. Generate neurons, astrocytes, oligodendrocytes.

**Intestinal stem cells (ISCs):** Base of crypts. Lgr5+. Rapidly cycling (~daily divisions).

**Mesenchymal stem cells (MSCs):** Bone marrow, adipose. Differentiate to osteoblasts, adipocytes, chondrocytes.

**Stem cell niche:** Microenvironment regulating stem cell behavior via supporting cells, ECM, signaling molecules, hypoxia.

## 2.21 Age-Related Changes in Stem Cells

**HSCs:**
- **Number:** Paradoxically increases with age (young: 10-30k, old: 50-100k in mice)
- **Function:** Declines despite increased numbers
  - Reduced repopulation efficiency
  - Lineage skewing: myeloid bias (more myeloid, fewer lymphocytes)
  - Clonal hematopoiesis (CHIP): oligoclonal expansion
  - Loss of quiescence

**Mechanisms:**
- Inflammation (SASP: TNF-α, IL-1β → NF-κB → reduced self-renewal)
- DNA damage accumulation
- Epigenetic drift
- Mitochondrial dysfunction
- Niche aging (stromal cells show senescence, SASP)

**Muscle satellite cells:**
- **Number:** Declines 30-50%
- **Quiescence:** Become "deeply quiescent"—unresponsive
- **Activation:** Defects, proliferate slowly
- **Differentiation:** Impaired fusion

**Mechanisms:**
- Niche aging: senescent fibroblasts produce SASP
- FGF2 increase → fibrogenic shift
- p16 upregulation
- NAD⁺ decline
- Notch signaling loss

**Neural stem cells:**
- **Number:** Declines 80-90% (SGZ neurogenesis)
- **Proliferation:** Reduced
- **Quiescence → dormancy:** Irreversible

**Mechanisms:**
- Niche inflammation (activated microglia)
- Reduced growth factors (BDNF, FGF2, VEGF)
- Wnt signaling decline
- Vascular deterioration

**Intestinal stem cells:**
- **Number:** Maintained or slightly increased
- **Function:** Increased error rates, reduced regeneration
- **Differentiation:** Skewing (fewer Paneth cells)

## 2.22 Intrinsic vs. Extrinsic Contributions

**Heterochronic parabiosis:** Joining circulatory systems of young and old mice.

**Findings:**

**Muscle (Conboy et al., 2005):**
- Old + young blood → satellite cell function improves
- Young + old blood → function declines
- **Interpretation:** Extrinsic factors dominate (at least partially reversible)

**Neurogenesis (Villeda et al., 2011, 2014):**
- Old + young blood → increased neurogenesis
- Young + old blood → reduced neurogenesis
- **Identified factors:** CCL11 (increases with age, inhibits), β2-microglobulin (increases, impairs), GDF11 (controversial)

**HSCs:** Intrinsic effects dominate, but young niche partially rescues.

**Blood-borne factors:**

**Increase with age (inhibitory):**
- CCL11, β2-microglobulin, TGF-β

**Decrease with age (beneficial):**
- TIMP2, oxytocin

**Plasma dilution:** Replacing 50% old plasma with saline+albumin improves function (Mehdipour et al., 2020), suggesting removing "bad" factors sufficient.

## 2.23 Reversibility

**Evidence:**

**Exercise:** Increases satellite cells, neurogenesis (BDNF)

**Caloric restriction:** Preserves HSC, satellite cell, NSC function

**Young blood exposure:** Partially restores function

**NAD⁺ restoration (NMN):** Improves satellite cell activation (Zhang et al., 2016)

**Senolytics:** Clearing senescent cells improves stem cells

**Partial reprogramming (OSKM):** Resets epigenetic age, improves function

**Limits:**
- DNA mutations irreversible (without gene editing)
- Telomere attrition (without telomerase)
- Structural damage (fibrosis, ECM crosslinking)

---

# II.G LOSS OF PROTEOSTASIS

## 2.24 Proteostasis Networks

**Proteostasis** = protein homeostasis (synthesis, folding, degradation).

**Key systems:**

**1. Molecular chaperones:**
- **HSP90:** Assists kinases, nuclear receptors
- **HSP70:** Prevents aggregation, binds unfolded proteins
- **HSP60 (chaperonins):** Encloses proteins in barrel for folding
- **Small HSPs:** HSP27, αB-crystallin

**2. Ubiquitin-Proteasome System (UPS):**
- Ubiquitination: E1 → E2 → E3 (substrate specificity)
- K48 polyubiquitin chains → proteasomal degradation
- **26S Proteasome:** 20S core (proteolytic) + 19S regulatory

**3. Autophagy-lysosome:**
- **Macroautophagy:** ULK1 initiation → phagophore → autophagosome → lysosome fusion
- **Chaperone-mediated autophagy (CMA):** KFERQ motif recognition by HSC70 → LAMP2A translocation
- **Microautophagy:** Direct lysosomal invagination

**4. Unfolded Protein Response (UPR):**
- ER stress sensors: IRE1α, PERK, ATF6
- Responses: Reduce protein load, increase chaperones, increase ERAD

## 2.25 Proteostasis Decline with Aging

**Protein aggregation increases:**
- Ubiquitinated aggregates in neurons (Lewy bodies, tangles), muscle, liver
- Specific proteins: Aβ, tau, α-synuclein, TDP-43
- Lipofuscin (autofluorescent "age pigment")

**Mechanisms:**

**1. Chaperone dysfunction:**
- HSF1 activation blunted (~30-50% reduced HSP induction)
- Chronic stress → desensitization
- Reduced NAD⁺ → impaired SIRT1 → reduced HSF1
- Chaperone overload

**2. Proteasome dysfunction:**
- 26S activity declines 30-60%
- Oxidative damage to catalytic subunits
- Reduced assembly (19S regulatory)
- Subunit expression decline
- Aggregate clogging

**3. Autophagy decline:**
- mTORC1 hyperactivation → ULK1 inhibition
- AMPK decline → reduced activation
- Reduced Beclin-1
- Lysosomal dysfunction:
  - Reduced TFEB nuclear translocation
  - Lysosomal pH increases
  - Reduced cathepsin activity
  - Lipofuscin accumulation
- Reduced LAMP2A (CMA decline ~80%)

**4. UPR dysregulation:**
- Chronic ER stress (elevated BiP, phospho-eIF2α)
- Blunted inducible UPR
- BiP levels decline despite chronic stress

## 2.26 Protein Aggregation Diseases

**Alzheimer's:**
- Aβ oligomers/plaques, hyperphosphorylated tau/tangles
- Impaired proteostasis contributes

**Parkinson's:**
- α-Synuclein aggregates (Lewy bodies)
- Parkin mutations → impaired mitophagy → accumulation

**Huntington's:**
- Polyglutamine-expanded huntingtin aggregates
- Proteostasis collapse in striatum

**ALS:**
- TDP-43, FUS aggregates

**Cataracts:**
- Crystallin aggregation (>80% incidence by age 80)

**Common themes:**
- Aggregation-prone proteins
- Proteostasis failure to clear
- Aggregates impair proteostasis (vicious cycle)
- Prion-like spreading (tau, α-synuclein)

---

# II.H ALTERED INTERCELLULAR COMMUNICATION

## 2.27 Inflammation and Inflammaging

**Inflammaging** (Franceschi et al., 2000): Chronic, low-grade, sterile inflammation characterizing aging.

**Biomarkers:**
- IL-6 (increases 2-4× from age 20 to 80)
- IL-1β, TNF-α, IL-18
- CRP, serum amyloid A
- Correlate with mortality, frailty, cognitive decline

**Sources:**

**1. Cellular senescence (SASP):** IL-6, IL-8, IL-1α, TNF-α

**2. Immunosenescence:**
- Thymic involution (90% loss by age 50) → reduced naive T cells
- T cell exhaustion (CD28-, CD57+)
- B cell dysfunction
- Myeloid skewing
- Innate activation (macrophages, microglia M1 polarization)

**3. Microbiome dysbiosis:**
- Reduced diversity
- Decreased Firmicutes (butyrate producers)
- Increased Proteobacteria
- Leaky gut → LPS translocation

**4. Mitochondrial DAMPs:**
- mtDNA (unmethylated CpG) → TLR9 → IL-6, IL-1β
- Cardiolipin → NLRP3 inflammasome
- N-formyl peptides

**5. NAD⁺ decline and CD38:**
- CD38 (NADase) increases → inflammation
- cADPR production → M1 polarization

**6. Adipose inflammation:**
- Visceral adipose expansion
- Macrophage infiltration (crown-like structures)
- ATMs secrete TNF-α, IL-6

**7. NF-κB hyperactivation:**
- Chronic low-level activation
- Reduced negative feedback
- Epigenetic accessibility at NF-κB targets

## 2.28 ECM Remodeling

**Collagen crosslinking:**
- AGEs (advanced glycation end-products) create irreversible crosslinks
- Arterial stiffening → hypertension
- Skin stiffening → wrinkles
- Accelerated by hyperglycemia, oxidative stress

**Elastin degradation:**
- Elastic fibers fragment
- Skin, lungs, arteries lose recoil
- Half-life ~70 years

**Proteoglycan loss:**
- Cartilage loses aggrecan → osteoarthritis

**MMP dysregulation:**
- Increased MMP-1, MMP-3, MMP-9 (skin)
- SASP role: senescent fibroblasts secrete MMPs

## 2.29 Endocrine Changes

**GH/IGF-1 decline:**
- GH secretion decreases 14%/decade after age 20
- IGF-1 at 60-80 is ~50% of young adult
- Consequences: sarcopenia, increased adiposity, osteoporosis
- **Paradox:** In model organisms, *reduced* IGF-1 extends lifespan

**Sex hormones:**
- **Menopause:** Estrogen/progesterone decline at ~50
- **Andropause:** Testosterone declines ~1%/year after 30

**DHEA:** Declines ~80% from 20 to 70

**Thyroid:** Subclinical hypothyroidism increases with age

---

# III. REJUVENATION STRATEGIES

## III.A PHARMACOLOGICAL INTERVENTIONS

### III.A.1 SENOLYTICS

#### 3.1 Rationale and Discovery

**Design principle:** Exploit senescent cell vulnerabilities. Senescent cells resist apoptosis via upregulation of pro-survival pathways (BCL-2, PI3K/AKT, ephrin). Inhibiting these should selectively kill senescent cells.

**Discovery (Zhu et al., 2015):** Kirkland lab identified Senescent Cell Anti-Apoptotic Pathways (SCAPs). Screened inhibitors → **dasatinib + quercetin (D+Q)** synergistic.

#### 3.2 Dasatinib + Quercetin (D+Q)

**Dasatinib:**
- Tyrosine kinase inhibitor (SRC, ABL, ephrin receptors)
- Kills senescent preadipocytes, endothelial cells

**Quercetin:**
- Flavonoid
- Inhibits PI3K, BCL-2, serpines
- Kills senescent fibroblasts

**Synergy:** Different cell types rely on different SCAPs. D+Q covers broader spectrum.

**In vitro:** 60-80% senescent cell killing, <10% normal cell toxicity

**In vivo (mice - Xu et al., 2018):**
- Aged mice (24-27 months), D+Q weekly/bi-weekly for 4 months
- **Clearance:** p16+ cells reduced 25-50% (tissue-dependent)
- **Physical function:** Endurance +20-30%, grip strength +10%, gait improved
- **Vascular:** Arterial stiffness reversed, endothelial function improved
- **Metabolic:** Glucose tolerance, insulin sensitivity improved
- **Lifespan:** Not extended (mice already old at start)
- **Healthspan:** Clear improvement

**Human trials:**

**Hickson et al., 2019 (diabetic kidney disease):**
- 9 patients, D+Q for 3 days
- Reduced senescent cells in adipose, reduced SASP (MCP-1)

**Justice et al., 2019 (IPF):**
- 14 IPF patients, D+Q 3 days/week for 3 weeks
- Improved 6-minute walk, reduced frailty

**Ongoing:** CKD, COPD, Alzheimer's, osteoarthritis, frailty trials

**Dosing:** 100 mg dasatinib + 1000-2000 mg quercetin, intermittent (3 days/month)

**Safety:** Dasatinib has side effects (thrombocytopenia, bleeding risk) with chronic use; intermittent dosing may mitigate.

#### 3.3 Fisetin

**Mechanism:** Flavonoid (strawberries, apples), inhibits PI3K/AKT/mTOR, BCL-2. Activates autophagy, NRF2.

**In vivo (Yousefzadeh et al., 2018):**
- Aged mice, 100 mg/kg/day for 5 days/month
- Reduced senescent cells, improved function, ~10% lifespan extension (small study)

**Advantages:** Single compound, dietary (perceived safer)

**Disadvantages:** Lower potency, bioavailability concerns

**Human trials:** Ongoing (frailty, Alzheimer's, CKD). Dosing: 1000-2000 mg/day for 2 days/month.

#### 3.4 Other Senolytics

**Navitoclax (ABT-263):** BCL-2/BCL-xL inhibitor. Potent but severe thrombocytopenia.

**Galactose-modified prodrugs (SSK1):** Exploit SA-β-gal. High selectivity.

**Challenges:**
- Heterogeneity (no single senolytic kills all types)
- Identification in humans (biopsies invasive)
- Optimal dosing schedule unknown
- Long-term safety unknown
- Resistance possible

---

### III.A.2 NAD⁺ PRECURSORS

#### 3.7 Rationale

NAD⁺ declines 30-50% with age, impairing mitochondria, sirtuins, DNA repair. Supplementing precursors (NMN, NR) aims to restore levels.

**Why not NAD⁺ directly?** Oral NAD⁺ degraded in gut. IV NAD⁺ expensive, short half-life.

#### 3.8 NMN (Nicotinamide Mononucleotide)

**Chemistry:** MW 334 g/mol, soluble in water.

**Absorption:** Possibly via Slc12a8 transporter (Grozio et al., 2019). Controversy: may dephosphorylate to NR, then re-phosphorylate.

**Pharmacokinetics:**
- Mice: Oral 500 mg/kg → blood NMN peaks 5-15 min, tissue NAD⁺ increases 26% (liver), sustained 60 min
- Humans: 100-500 mg → blood NMN peaks 30 min, NAD⁺ increases 15-30%

#### 3.9 NMN Effects in Mice

**Metabolic (Yoshino et al., 2011):**
- 300 mg/kg/day for 12 months (aged mice starting at 17 months)
- NAD⁺ restored to youthful levels
- Improved glucose tolerance, insulin sensitivity
- Reduced hepatic triglycerides

**Physical (Das et al., 2018):**
- 24-month mice, 300 mg/kg/day for 2 months
- Grip strength +15%, endurance +50%
- Increased muscle capillary density
- Improved mitochondrial function

**Cardiovascular (De Picciotto et al., 2016):**
- 27-month mice, 500 mg/kg/day for 2 months
- Reduced arterial stiffness
- Improved endothelial function

**Cognitive (Tarantini et al., 2019):**
- Improved neurovascular coupling, cerebral blood flow
- Enhanced cognition in Alzheimer's models

**Lifespan:** No definitive study completed. Healthspan clear; lifespan uncertain.

#### 3.10 NR (Nicotinamide Riboside)

**Chemistry:** MW 255 g/mol. Lipophilic, crosses membranes easily.

**Absorption:** Via ENT1-4 transporters. Inside cells: NRK1/2 phosphorylate NR → NMN → NAD⁺.

**Pharmacokinetics (humans - Martens et al., 2018):**
- 1000 mg → +60% blood NAD⁺ at 8 hours
- 2000 mg → +90%

#### 3.11 NR Effects

**Metabolic (mice - Cantó et al., 2012):**
- High-fat diet obese mice, 400 mg/kg/day
- Reduced weight gain, improved insulin sensitivity
- No effect on lean mice

**Stem cells (Zhang et al., 2016):**
- 20-month mice, 400 mg/kg/day for 2 months
- Improved satellite cell activation, regeneration

**Lifespan:** No robust extension on standard diet. Healthspan benefits demonstrated.

#### 3.12 Human Trials

**NMN:**
- Liao et al., 2021: 250 mg/day for 10 weeks → increased muscle insulin sensitivity +25%
- Irie et al., 2022: 250 mg/day for 12 weeks → improved walking speed, grip strength (modest)

**NR:**
- Martens et al., 2018: 1000 mg/day for 6 weeks → BP reduction 5-8 mmHg (elevated baseline)
- Dollerup et al., 2018: 2000 mg/day for 12 weeks in obese men → no significant effects (disappointing)

**Summary:** Safe, increase blood NAD⁺. Clinical outcomes modest/inconsistent. Possible reasons: insufficient dosing, short duration, tissue NAD⁺ not measured, healthy participants.

#### 3.13 NMN vs. NR

**Arguments for NMN:** One step closer to NAD⁺, Slc12a8 transporter

**Arguments for NR:** Better bioavailability, ENT transporters ubiquitous

**Likely answer:** Minimal difference. Both work. Interconversion occurs.

**Dosing:** NMN 250-500 mg/day, NR 500-1000 mg/day

**Cost:** NMN $30-100/month, NR $40-80/month

#### 3.14 Safety

**Preclinical:** Mice up to 900 mg/kg/day for 12 months show no toxicity.

**Human:** Up to 2000 mg/day for 12 weeks excellent tolerability. Mild nausea rare.

**Theoretical concerns:**
- Cancer risk? (NAD⁺ required for proliferation) — No evidence. Cancer cells often have high NAD⁺ already.
- CD38 consumption if CD38 high

---

### III.A.3 mTOR INHIBITORS

#### 3.15 Rapamycin: Discovery and Mechanism

**Discovery:** From *Streptomyces hygroscopicus* (Easter Island), 1972. Immunosuppressant, FDA-approved 1999.

**Mechanism:**
- Binds FKBP12 → complex binds mTORC1 → allosteric inhibition
- Acutely mTORC1-specific; chronic can affect mTORC2

**Effects:**
- Inhibits protein synthesis, lipid synthesis
- Activates autophagy
- Alters metabolism

#### 3.16 Lifespan Extension Evidence

**Mice (ITP):**

**Harrison et al., 2009:**
- 14 ppm rapamycin (2.24 mg/kg/day) starting at 20 months (late life)
- Median lifespan: +9% (females), +13% (males)

**Miller et al., 2014:**
- Started at 9 months (middle age), 42 ppm (8 mg/kg/day)
- Median: +23% (males), +26% (females)

**Robustness:** Replicated across three sites, multiple cohorts. Most robust lifespan intervention.

**Non-mammalian:**
- Yeast: TOR1 deletion → 30% extension
- Worms: TOR RNAi → ~20%
- Flies: dTOR reduction → 10-15%

#### 3.17 Healthspan Effects

**Cognitive:** Improved learning/memory, reduced Alzheimer's pathology

**Cardiac:** Preserved function, reduced hypertrophy/fibrosis

**Immune:** Rejuvenated vaccine response (Chen et al., 2009)

**Cancer:** Reduced tumor incidence

**Broad tissue benefits** suggest systemic aging modulation.

#### 3.18 Mechanisms

**Multiple proposed:**
1. Autophagy induction
2. Protein synthesis reduction
3. Mitochondrial function improvement
4. Reduced inflammation
5. Stem cell preservation
6. IIS modulation

Likely multi-factorial.

#### 3.19 Human Translation

**Current use:**
- Transplant: chronic 1-5 mg/day (immunosuppression)
- Cancer: rapalogs (everolimus, temsirolimus)

**Side effects (chronic high-dose):**
- Immunosuppression
- Insulin resistance, hyperglycemia
- Hyperlipidemia
- Oral ulcers (~40%)
- Impaired wound healing
- Testicular dysfunction
- Pneumonitis (rare)

**Intermittent dosing:** Weekly/bi-weekly may preserve benefits, reduce side effects.

**PEARL trial (Mannick et al., 2014, 2018):**
- Elderly ≥65 years, everolimus 0.5 mg daily or 5 mg weekly for 6 weeks
- **Results:** Improved influenza vaccine response (~20% increase), reduced infections
- **Interpretation:** Low-dose rapamycin improves immune function in elderly

**Challenges:** Aging not FDA-recognized disease. Off-label use growing (5-10 mg weekly common in longevity community).

#### 3.20 Rapalogs

**Everolimus (RAD001):** Shorter half-life (~30 hrs vs. 60). Extends mouse lifespan ~10%.

**Temsirolimus:** Prodrug. Used in renal cell carcinoma.

Rapalogs partially avoid side effects but still have immunosuppression, metabolic effects.

---

## III.B EPIGENETIC REPROGRAMMING

### 3.21 Yamanaka Factors: Discovery

**Takahashi & Yamanaka, 2006:**
- Four transcription factors: **Oct4, Sox2, Klf4, c-Myc (OSKM)**
- Reprogram mouse fibroblasts → induced pluripotent stem cells (iPSCs)

**2007:** Human fibroblasts reprogrammed using same factors.

**Nobel Prize 2012:** Yamanaka awarded.

### 3.22 Mechanisms of Reprogramming

**OSKM functions:**

**Oct4:** Master pluripotency regulator. Activates pluripotency genes, represses differentiation.

**Sox2:** Partner of Oct4. Cooperatively bind DNA.

**Klf4:** Pioneer factor, facilitates chromatin opening.

**c-Myc:** Oncogene, promotes proliferation. Enhances efficiency ~10-fold but tumorigenic.

**Reprogramming phases:**
- Initiation (Days 0-3): Chromatin remodeling, MET
- Maturation (Days 3-9): Proliferation increase, metabolic shift
- Stabilization (Days 9-21): Exogenous OSKM silenced, endogenous take over, telomerase reactivated

**Endpoint:** Epigenetic age resets to ~zero.

### 3.23 Partial Reprogramming

**Key insight:** Full reprogramming erases identity (fibroblast → iPSC). For rejuvenation, want to reverse aging **without** losing identity.

**Partial reprogramming hypothesis:** Transient OSKM reverses epigenetic age without completing full reprogramming.

**Ocampo et al., 2016 (landmark):**

**Model:** Progeria mice (HGPS)

**Intervention:** Inducible OSKM, cyclic expression (2 days ON, 5 days OFF)

**Results:**
- Lifespan: +50% (20 → 30 weeks median)
- Phenotype: Reduced kyphosis, alopecia, weight loss. Improved muscle, cardiovascular function.
- Molecular: Epigenetic age reversal, reduced DNA damage, improved mitochondria
- **Crucially: No teratomas**

**Naturally aged mice:**
- Improved regeneration, metabolic parameters

**Gill et al., 2022 (Lu/Sinclair):**

**Model:** Aged mice, optic nerve crush

**Intervention:** AAV-OSKM (or OSK) to retinal ganglion cells

**Results:**
- Vision restoration: visual acuity improved ~50%
- Epigenetic rejuvenation: DNA methylation age reversed
- **Mechanism:** Requires Tet1/Tet2 (DNA demethylases)

### 3.24 Mechanisms of Age Reversal

**1. DNA methylation remodeling:**
- Global demethylation (hypermethylated sites)
- Focal remethylation (youthful patterns)
- TETs upregulated by OSKM

**2. Histone modification changes:**
- Increased H3K4me3 at pluripotency genes
- Reduced H3K27me3, H3K9me3
- Global acetylation increase

**3. Chromatin accessibility:**
- Nucleosome remodeling
- Heterochromatin decompaction

**4. Resetting damage markers:**
- p16, p21 decrease
- γ-H2AX reduced

**5. Mitochondrial rejuvenation:**
- Function improves (ATP, reduced ROS)

**6. Metabolic shifts:**
- Transient glycolysis shift, then return

### 3.25 Temporal Control

**Duration determines outcome:**

| OSKM Expression | Duration | Outcome |
|-----------------|----------|---------|
| Constitutive | Weeks | Full reprogramming → iPSCs → teratomas |
| Long cyclic (4 on, 3 off) | Months | Partial reprogramming → possible dysplasia |
| Short cyclic (2 on, 5 off) | Months | Rejuvenation ✅ |
| Very brief (1 day) | Single | Minimal effect |

**Optimal:** 2 days on, 5 off (Ocampo 2016). Allows cells to "rest," re-establish identity.

### 3.26 Safety Concerns

**Teratomas:**
- Ocampo 2016: No teratomas with cyclic OSKM (2 on, 5 off)
- Constitutive: teratomas within weeks

**c-Myc oncogenicity:**
- Solution: Use OSK (without c-Myc). Reduces efficiency but safer.

**Dysplasia:**
- Browder et al., 2022: Hyperplastic lesions with prolonged OSKM (not frank tumors but concerning)

**Immune response:**
- OSKM are embryonic proteins. Minimal immune infiltration in studies but long-term unexplored.

**Insertional mutagenesis:**
- Solution: Non-integrating vectors (AAV, mRNA)

### 3.27 Alternative Approaches

**Chemical reprogramming:**
- Small molecules replacing OSKM
- Hou et al., 2013: 7-molecule cocktail, very low efficiency (<0.1%)
- Advantages: No genetic modification
- Challenges: Prolonged treatment, mechanisms unclear

**Modified factor cocktails:**
- OSK (no c-Myc)
- OSNL (Oct4, Sox2, Nanog, Lin28)
- Tet1 alone (Gill et al., 2022 showed some effects)

**Delivery:**
- Viral: Retrovirus/lentivirus (integrate, risky), AAV (doesn't integrate, safer, used in Gill 2022)
- Non-viral: mRNA (transient, no integration, in development), proteins (inefficient)

**Current focus:** AAV for in vivo; mRNA for repeated cyclic dosing.

---

## III.C CRISPR APPLICATIONS

### 3.28 CRISPR Overview

**Mechanism:**
- Cas9 protein + guide RNA
- gRNA binds target DNA
- Cas9 cleaves (DSB)
- Repair: NHEJ (error-prone, knockout) or HDR (precise editing, requires template)

**Nobel Prize 2020:** Doudna & Charpentier

### 3.29 CRISPR for Aging

**Targeting aging genes:**

**1. p16 knockout:**
- p16 drives senescence. Deletion prevents senescence.
- Concern: tumor suppressor, knockout → cancer risk
- CRISPR: Could knock out in non-cancer-risk tissues. Not tested.

**2. Klotho upregulation:**
- Anti-aging protein. Overexpression extends lifespan 20-30% (mice).
- CRISPR: Insert additional copies or CRISPRa. Preclinical.

**3. TERT reactivation:**
- CRISPR: Activate TERT gene (CRISPRa) or insert cassette.
- Concern: Cancer (TERT in 85-90% cancers). Requires tumor suppressor co-expression.

**4. Lamin A correction (progeria):**
- CRISPR corrects LMNA mutation in patient cells (Santiago et al., 2020).

**Challenges:**
- **Delivery:** Large components. AAV barely fits. LNPs deliver mRNA.
- **Off-targets:** High-fidelity Cas9 variants mitigate.
- **Mosaicism:** Not all cells edited.
- **Immune response:** Anti-Cas9 antibodies in ~50% humans.

### 3.29 Epigenome Editing

**dCas9** (catalytically dead) fused to epigenetic modifiers.

**CRISPRa (activation):**
- dCas9-VP64 or dCas9-VPR
- Activate Klotho, TERT, antioxidant genes
- Proof-of-concept in cells; limited in vivo

**CRISPRi (interference):**
- dCas9-KRAB
- Silence p16, inflammatory genes
- Reversible (no permanent DNA change)

**Epigenetic remodeling:**
- dCas9-DNMT3A: Add methylation (remethylate hypomethylated regions)
- dCas9-TET1: Remove methylation (demethylate hypermethylated promoters)
- Proof-of-concept (Liu et al., 2016; Xu et al., 2016)

**For aging:**
- **Hypothesis:** Targeted epigenetic editing reverses drift, resets clocks without OSKM.
- **Advantages:** More precise, safer (no pluripotency risk)
- **Challenges:** Which sites to target? Horvath clock has 353 CpGs. Multiplexing complex.

**Status:** Research stage. No in vivo aging studies yet.

**Histone modification editing:**
- dCas9-p300 (histone acetyltransferase): Activate enhancers (Hilton et al., 2015)
- dCas9-LSD1 (demethylase): Remove methyl groups

**Applications to aging:** Hypothetical. Not tested.

---

## III.D STEM CELL THERAPIES

### 3.30 HSC Transplantation

**Standard procedure:** Used for leukemia, lymphoma, aplastic anemia. Donor HSCs transplanted after ablative conditioning.

**For aging?**

**Young-to-old HSC transplant (mice):**
- Young HSCs → aged recipients restore immune function (Janzen et al., 2006)
- Lifespan effect ambiguous (conditioning toxic)

**Challenges:**
- Conditioning toxicity (irradiation/chemo)
- GVHD (graft-versus-host disease)
- Cost/risk (~$500k-1M, 10-30% mortality)

**For healthy aging:** Impractical. But informs niche-targeting approaches.

### 3.31 MSC Therapy

**MSCs:** Multipotent (bone marrow, adipose, umbilical cord). Differentiate to osteoblasts, adipocytes, chondrocytes.

**Clinical use:** FDA-approved for GVHD. >1000 trials (osteoarthritis, heart failure, stroke, frailty).

**Mechanisms (not primarily differentiation):**

**Paracrine:**
- Secrete VEGF, HGF, IGF-1, IL-10, TGF-β, exosomes
- Reduce inflammation, promote angiogenesis, stimulate endogenous stem cells

**Immunomodulation:**
- Suppress excessive immune responses

**Evidence (mice):**

**Shen et al., 2011:** Young MSCs → aged mice improved function, no lifespan data.

**Lunyak et al., 2017:** Hypothalamic MSC injection → 10% lifespan extension, improved healthspan.

**Human trials:**

**CRATUS (Golpanian et al., 2017):**
- 30 frail elderly, allogeneic MSCs (100-200 million, IV)
- Safe. Modest function improvement (6-minute walk +20 meters at 6 months). Reduced CRP, TNF-α.

**MILES:** Phase II RCT ongoing. Preliminary: safe, trends toward improvement.

**Challenges:**
- Heterogeneity (preparations vary)
- Mechanism unclear
- Don't engraft long-term (cleared days-weeks)
- Effects transient unless repeated

**Exosome therapy:** Emerging alternative. Purify exosomes from MSCs, deliver those. Easier storage, no live cells.

### 3.32-3.34 iPSC-Derived Cell Replacement

**Workflow:**
1. Patient somatic cells → iPSCs (OSKM)
2. Differentiate iPSCs → desired cell type
3. Transplant back

**Advantages:** Autologous (no rejection), unlimited supply, quality control

**Applications:**
- Parkinson's (iPSC-derived dopaminergic neurons)
- AMD (iPSC-derived RPE)
- Heart failure (iPSC-derived cardiomyocytes)

**Trials:**

**Parkinson's (Kyoto, 2018-ongoing):** Phase I safe, cells survived, modest motor improvement.

**AMD (RIKEN, 2014):** Safe, vision stabilized.

**Heart (Osaka, 2020):** Phase I safe, ejection fraction +5%.

**Challenges:**
- Differentiation efficiency (cells "fetal-like")
- Tumorigenicity (undifferentiated iPSCs → teratomas; rigorous purification required)
- Integration (form connections?)
- Cost/time (months, $50k-500k per patient)
- Immune response even with autologous

**Organoids & bioprinting:**
- Organoids: 3D tissue structures. Drug testing, disease modeling. Transplantation early stage.
- 3D bioprinting: Print tissues. Simple (skin, cartilage) feasible; complex organs (heart, kidney) not yet.

---

## KEY REFERENCES - PART 2

Baker, D. J., et al. (2011). Clearance of p16+ cells delays aging. *Nature*, 479, 232-236.

Baker, D. J., et al. (2016). p16+ cells shorten healthspan. *Nature*, 530, 184-189.

Camacho-Pereira, J., et al. (2016). CD38 dictates NAD decline. *Cell Metabolism*, 23, 1127-1139.

Conboy, I. M., et al. (2005). Rejuvenation by young environment. *Nature*, 433, 760-764.

Cuervo, A. M., & Dice, J. F. (2000). CMA decline with age. *JBC*, 275, 31505-31513.

Das, A., et al. (2018). NAD+-H2S signaling and vascular aging. *Cell*, 173, 74-89.

Franceschi, C., et al. (2000). Inflamm-aging. *Ann NY Acad Sci*, 908, 244-254.

Gill, D., et al. (2022). Multi-omic rejuvenation by transient reprogramming. *eLife*, 11, e71624.

Golpanian, S., et al. (2017). MSCs for frailty. *J Gerontol A*, 72, 1505-1512.

Grozio, A., et al. (2019). Slc12a8 is NMN transporter. *Nature Metabolism*, 1, 47-57.

Herranz, N., et al. (2015). mTOR regulates SASP. *Nature Cell Biology*, 17, 1205-1217.

Hickson, L. J., et al. (2019). Senolytics in diabetic kidney disease. *EBioMedicine*, 47, 446-456.

Jaskelioff, M., et al. (2011). Telomerase reverses tissue degeneration. *Nature*, 469, 102-106.

Justice, J. N., et al. (2019). Senolytics in IPF. *EBioMedicine*, 40, 554-563.

Laberge, R. M., et al. (2015). mTOR promotes IL1A translation. *Nature Cell Biology*, 17, 1049-1061.

Mannick, J. B., et al. (2014). mTOR inhibition improves immune function. *Science Translational Medicine*, 6, 268ra179.

Martens, C. R., et al. (2018). NR elevates NAD+ in adults. *Nature Communications*, 9, 1286.

Mehdipour, M., et al. (2020). Rejuvenation by plasma exchange. *Aging*, 12, 8790-8819.

Ocampo, A., et al. (2016). Partial reprogramming ameliorates aging. *Cell*, 167, 1719-1733.

Sousa-Victor, P., et al. (2014). Muscle stem cells switch to senescence. *Nature*, 506, 316-321.

Villeda, S. A., et al. (2011). Ageing systemic milieu impairs neurogenesis. *Nature*, 477, 90-94.

Villeda, S. A., et al. (2014). Young blood reverses cognitive impairments. *Nature Medicine*, 20, 659-663.

Xu, M., et al. (2018). Senolytics improve function and lifespan. *Nature Medicine*, 24, 1246-1256.

Yoshino, J., et al. (2011). NMN treats diet-induced diabetes. *Cell Metabolism*, 14, 528-536.

Yousefzadeh, M. J., et al. (2018). Fisetin extends healthspan. *EBioMedicine*, 36, 18-28.

Zhang, H., et al. (2016). NAD+ improves stem cells and lifespan. *Science*, 352, 1436-1443.

Zhu, Y., et al. (2015). SCAPs to senolytic drugs. *Aging Cell*, 14, 644-658.

---

**END OF PART 2**

**Continue to Part 3 for:**
- Remaining Interventions (Metformin, Exercise, Caloric Restriction)
- Clinical Landscape
- Future Directions
- Comprehensive Bibliography
- Summary Tables
- Glossary
- Final Synthesis